Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) is one of the most promising stocks according to Wall Street analysts. On June 26, ...

Intermittent treatment with pimecrolimus over 1 year significantly reverses corticosteroid-induced skin atrophy and ...

WILMINGTON, Del. - The U.S. Food and Drug Administration has extended its review period for Incyte’s (NASDAQ:INCY) supplemental New Drug Application for ruxolitinib cream (Opzelura) in children aged 2 ...

Organon’s VTAMA ® (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis. The American Academy of ...

Spongiotic dermatitis describes skin inflammation that causes swelling, redness, and itching. It's most often associated with ...

ZORYVE cream, 0.3%, is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older. ZORYVE cream, 0.15%, is indicated ...

A panelist discusses how real-world data presented at the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) demonstrates that initiating ruxolitinib cream therapy for atopic ...

Introduction Limited by the specific location of atopic facial dermatitis, treatment options for atopic dermatitis are limited. Our previous research confirms that BiShengZhiYan cream (BSZY cream) can ...

The“INterventional Trial EvaluatinG roflUMilast cream for the treatmENt of aTopic dermatitis” Open Label Extension (INTEGUMENT-OLE) was a Phase 3, multicenter, open-label extension study of ...

Efficacy and Tolerability of Roflumilast Cream 0.15% for Atopic Dermatitis: Pooled Subgroup Analysis of Patients with Face/Eyelid Involvement from Phase 3 INTEGUMENT-1/2 TrialsSimpson, E et al.